Skip to main content
Top
Published in: Pituitary 2/2022

Open Access 01-04-2022 | Neuropathic Pain

Low prevalence of neuropathic-like pain symptoms in long-term controlled acromegaly

Authors: Victoria R. van Trigt, Iris C. M. Pelsma, Herman M. Kroon, Alberto M. Pereira, Coen van der Meulen, Margreet Kloppenburg, Nienke R. Biermasz, Kim M. J. A. Claessen

Published in: Pituitary | Issue 2/2022

Login to get access

Abstract

Purpose

Pain is a common symptom of acromegaly, impairing health-related quality of life (HR-QoL) significantly despite long-term disease remission. Neuropathic-like pain (NP-like) symptoms are invalidating, with great impact on HR-QoL. Studies characterizing or investigating the etiology of pain in acromegaly are scarce. Therefore, we aimed to assess NP-like symptoms in a cohort of controlled acromegaly patients.

Methods

Forty-four long-term controlled acromegaly patients (aged 62.6 ± 12.6 years; 56.8% female) were included in this cross-sectional study. NP-like symptoms were assessed using the validated painDETECT questionnaire. Patients were divided in three probability-based NP-like symptoms categories based on the total score (range 0–35): unlikely (≤ 12), indeterminate (13–18) and likely (≥ 19). HR-QoL (physical component score (PCS), and mental component score (MCS)), and self-reported pain were assessed using Short Form-36 (SF-36). Potential risk factors were determined using linear regression analyses.

Results

Self-reported pain was reported by 35 patients (79.5%). Likely NP-like symptoms were present in 4/44 patients (9.1%), and indeterminate NP-like symptoms in 6/44 patients (13.6%). All patients with likely NP-like symptoms were female. Higher painDETECT scores were negatively associated with HR-QoL (PCS: r = − 0.46, P = 0.003; MCS: r = − 0.37, P = 0.018), and SF-36 pain scores (r = − 0.63, P < 0.0001). Female sex was a risk factor for NP-like symptoms.

Conclusions

Pain was prevalent in controlled acromegaly patients, whereas NP-like symptoms were relatively infrequent, and only observed in females. NP-like symptoms were associated with lower HR-QoL in acromegaly. Since specific analgesic therapy is available, awareness for characterization, increased understanding, and clinical trials regarding neuropathic pain identification and treatment in acromegaly patients are warranted.
Appendix
Available only for authorised users
Literature
1.
go back to reference Wassenaar M et al (2010) Clinical osteoarthritis predicts physical and psychological QoL in acromegaly patients. Growth Hormon IGF Res 20:226–233 Wassenaar M et al (2010) Clinical osteoarthritis predicts physical and psychological QoL in acromegaly patients. Growth Hormon IGF Res 20:226–233
2.
go back to reference Broersen LHA et al (2021) Improvement in symptoms and health-related quality of life in acromegaly patients: a systematic review and meta-analysis. J Clin Endocrinol Metab 106(2):577–587PubMed Broersen LHA et al (2021) Improvement in symptoms and health-related quality of life in acromegaly patients: a systematic review and meta-analysis. J Clin Endocrinol Metab 106(2):577–587PubMed
3.
go back to reference Dimopoulou C et al (2014) Clinical characteristics of pain in patients with pituitary adenomas. Eur J Endocrinol 171(5):581–591PubMed Dimopoulou C et al (2014) Clinical characteristics of pain in patients with pituitary adenomas. Eur J Endocrinol 171(5):581–591PubMed
5.
go back to reference Vilar L et al (2017) Acromegaly: clinical features at diagnosis. Pituitary 20(1):22–32PubMed Vilar L et al (2017) Acromegaly: clinical features at diagnosis. Pituitary 20(1):22–32PubMed
6.
go back to reference Kyriakakis N et al (2017) Impaired quality of life in patients with treated acromegaly despite long-term biochemically stable disease: Results from a 5-years prospective study. Clin Endocrinol (Oxf) 86(6):806–815 Kyriakakis N et al (2017) Impaired quality of life in patients with treated acromegaly despite long-term biochemically stable disease: Results from a 5-years prospective study. Clin Endocrinol (Oxf) 86(6):806–815
7.
go back to reference Kameyama S et al (1993) Subclinical carpal tunnel syndrome in acromegaly. Neurol Med Chir (Tokyo) 33(8):547–551 Kameyama S et al (1993) Subclinical carpal tunnel syndrome in acromegaly. Neurol Med Chir (Tokyo) 33(8):547–551
8.
go back to reference Abreu A et al (2016) Challenges in the diagnosis and management of acromegaly: a focus on comorbidities. Pituitary 19(4):448–457PubMedPubMedCentral Abreu A et al (2016) Challenges in the diagnosis and management of acromegaly: a focus on comorbidities. Pituitary 19(4):448–457PubMedPubMedCentral
9.
go back to reference Claessen KM et al (2012) Progression of acromegalic arthropathy despite long-term biochemical control: a prospective, radiological study. Eur J Endocrinol 167(2):235–244PubMed Claessen KM et al (2012) Progression of acromegalic arthropathy despite long-term biochemical control: a prospective, radiological study. Eur J Endocrinol 167(2):235–244PubMed
10.
go back to reference Wassenaar MJ et al (2011) High prevalence of vertebral fractures despite normal bone mineral density in patients with long-term controlled acromegaly. Eur J Endocrinol 164(4):475–483PubMed Wassenaar MJ et al (2011) High prevalence of vertebral fractures despite normal bone mineral density in patients with long-term controlled acromegaly. Eur J Endocrinol 164(4):475–483PubMed
11.
go back to reference Claessen KM et al (2014) Increased clinical symptoms of acromegalic arthropathy in patients with long-term disease control: a prospective follow-up study. Pituitary 17(1):44–52PubMed Claessen KM et al (2014) Increased clinical symptoms of acromegalic arthropathy in patients with long-term disease control: a prospective follow-up study. Pituitary 17(1):44–52PubMed
12.
go back to reference Giustina A (2020) Acromegaly and vertebral fractures: facts and questions. Trends Endocrinol Metab 31(4):274–275PubMed Giustina A (2020) Acromegaly and vertebral fractures: facts and questions. Trends Endocrinol Metab 31(4):274–275PubMed
14.
go back to reference Mazziotti G et al (2015) Bone turnover, bone mineral density, and fracture risk in acromegaly: a meta-analysis. J Clin Endocrinol Metab 100:384–394 Mazziotti G et al (2015) Bone turnover, bone mineral density, and fracture risk in acromegaly: a meta-analysis. J Clin Endocrinol Metab 100:384–394
15.
go back to reference Jadresic A et al (1982) The acromegaly syndrome. Relation between clinical features, growth hormone values and radiological characteristics of the pituitary tumours. Q J Med 51(202):189–204PubMed Jadresic A et al (1982) The acromegaly syndrome. Relation between clinical features, growth hormone values and radiological characteristics of the pituitary tumours. Q J Med 51(202):189–204PubMed
17.
go back to reference Bouhassira D et al (2008) Prevalence of chronic pain with neuropathic characteristics in the general population. Pain 136(3):380–387PubMed Bouhassira D et al (2008) Prevalence of chronic pain with neuropathic characteristics in the general population. Pain 136(3):380–387PubMed
18.
go back to reference Smith BH et al (2007) Health and quality of life associated with chronic pain of predominantly neuropathic origin in the community. Clin J Pain 23(2):143–149PubMed Smith BH et al (2007) Health and quality of life associated with chronic pain of predominantly neuropathic origin in the community. Clin J Pain 23(2):143–149PubMed
19.
go back to reference Chanson P et al (2009) Pituitary tumours: acromegaly. Best Pract Res Clin Endocrinol Metab 23(5):555–574PubMed Chanson P et al (2009) Pituitary tumours: acromegaly. Best Pract Res Clin Endocrinol Metab 23(5):555–574PubMed
20.
go back to reference Kopsky DJ, KeppelHesselink JM (2013) Neuropathic pain as a result of acromegaly, treated with topical baclofen cream. J Pain Symptom Manage 46(4):4–5 Kopsky DJ, KeppelHesselink JM (2013) Neuropathic pain as a result of acromegaly, treated with topical baclofen cream. J Pain Symptom Manage 46(4):4–5
21.
go back to reference Hannon AM, Thompson CJ, Sherlock M (2017) Diabetes in patients with acromegaly. Curr Diab Rep 17(2):8PubMed Hannon AM, Thompson CJ, Sherlock M (2017) Diabetes in patients with acromegaly. Curr Diab Rep 17(2):8PubMed
22.
go back to reference Finnerup NB, Sindrup SH, Jensen TS (2010) The evidence for pharmacological treatment of neuropathic pain. Pain 150(3):573–581PubMed Finnerup NB, Sindrup SH, Jensen TS (2010) The evidence for pharmacological treatment of neuropathic pain. Pain 150(3):573–581PubMed
23.
go back to reference Ohtori S et al (2013) Efficacy of combination of meloxicam and pregabalin for pain in knee osteoarthritis. Yonsei Med J 54(5):1253–1258PubMedPubMedCentral Ohtori S et al (2013) Efficacy of combination of meloxicam and pregabalin for pain in knee osteoarthritis. Yonsei Med J 54(5):1253–1258PubMedPubMedCentral
24.
go back to reference Pelsma ICM et al (2020) Progression of acromegalic arthropathy in long-term controlled acromegaly patients: 9 years of longitudinal follow-up. J Clin Endocrinol Metab 106:188 Pelsma ICM et al (2020) Progression of acromegalic arthropathy in long-term controlled acromegaly patients: 9 years of longitudinal follow-up. J Clin Endocrinol Metab 106:188
25.
go back to reference Biermasz NR et al (2012) Automated image analysis of hand radiographs reveals widened joint spaces in patients with long-term control of acromegaly: relation to disease activity and symptoms. Eur J Endocrinol 166(3):407PubMed Biermasz NR et al (2012) Automated image analysis of hand radiographs reveals widened joint spaces in patients with long-term control of acromegaly: relation to disease activity and symptoms. Eur J Endocrinol 166(3):407PubMed
26.
go back to reference Wassenaar MJ et al (2011) Arthropathy in long-term cured acromegaly is characterised by osteophytes without joint space narrowing: a comparison with generalised osteoarthritis. Ann Rheum Dis 70(2):320–325PubMed Wassenaar MJ et al (2011) Arthropathy in long-term cured acromegaly is characterised by osteophytes without joint space narrowing: a comparison with generalised osteoarthritis. Ann Rheum Dis 70(2):320–325PubMed
27.
go back to reference Wassenaar MJ et al (2009) The exon-3 deleted growth hormone receptor polymorphism predisposes to long-term complications of acromegaly. J Clin Endocrinol Metab 94(12):4671–4678PubMed Wassenaar MJ et al (2009) The exon-3 deleted growth hormone receptor polymorphism predisposes to long-term complications of acromegaly. J Clin Endocrinol Metab 94(12):4671–4678PubMed
28.
go back to reference Wassenaar MJ et al (2009) High prevalence of arthropathy, according to the definitions of radiological and clinical osteoarthritis, in patients with long-term cure of acromegaly: a case-control study. Eur J Endocrinol 160(3):357–365PubMed Wassenaar MJ et al (2009) High prevalence of arthropathy, according to the definitions of radiological and clinical osteoarthritis, in patients with long-term cure of acromegaly: a case-control study. Eur J Endocrinol 160(3):357–365PubMed
29.
go back to reference Wassenaar MJ et al (2010) Acromegaly is associated with an increased prevalence of colonic diverticula: a case-control study. J Clin Endocrinol Metab 95(5):2073–2079PubMed Wassenaar MJ et al (2010) Acromegaly is associated with an increased prevalence of colonic diverticula: a case-control study. J Clin Endocrinol Metab 95(5):2073–2079PubMed
30.
go back to reference Claessen KM et al (2013) Two phenotypes of arthropathy in long-term controlled acromegaly? A comparison between patients with and without joint space narrowing (JSN). Growth Horm IGF Res 23(5):159–164PubMed Claessen KM et al (2013) Two phenotypes of arthropathy in long-term controlled acromegaly? A comparison between patients with and without joint space narrowing (JSN). Growth Horm IGF Res 23(5):159–164PubMed
31.
go back to reference Claessen KMJA et al (2017) Acromegalic arthropathy in various stages of the disease: an MRI study. Eur J Endocrinol 176(6):779PubMed Claessen KMJA et al (2017) Acromegalic arthropathy in various stages of the disease: an MRI study. Eur J Endocrinol 176(6):779PubMed
32.
go back to reference van der Klaauw A et al (2008) Disease-specific impairments in quality of life during long-term follow-up of patients with different pituitary adenomas. Clin Endocrinol 69:775–784 van der Klaauw A et al (2008) Disease-specific impairments in quality of life during long-term follow-up of patients with different pituitary adenomas. Clin Endocrinol 69:775–784
33.
go back to reference Ross HA et al (2014) Harmonization of growth hormone measurement results: the empirical approach. Clin Chim Acta 432:72–76PubMed Ross HA et al (2014) Harmonization of growth hormone measurement results: the empirical approach. Clin Chim Acta 432:72–76PubMed
34.
go back to reference Cole TJ (1990) The LMS method for constructing normalized growth standards. Eur J Clin Nutr 44(1):45–60PubMed Cole TJ (1990) The LMS method for constructing normalized growth standards. Eur J Clin Nutr 44(1):45–60PubMed
35.
go back to reference Rikken B et al (1998) Plasma levels of insulin-like growth factor (IGF)-I, IGF-II and IGF-binding protein-3 in the evaluation of childhood growth hormone deficiency. Horm Res 50(3):166–176PubMed Rikken B et al (1998) Plasma levels of insulin-like growth factor (IGF)-I, IGF-II and IGF-binding protein-3 in the evaluation of childhood growth hormone deficiency. Horm Res 50(3):166–176PubMed
36.
go back to reference Rienstra W et al (2015) The modified painDETECT questionnaire for patients with hip or knee osteoarthritis: translation into Dutch, cross-cultural adaptation and reliability assessment. PLoS ONE 10(12):e0146119 Rienstra W et al (2015) The modified painDETECT questionnaire for patients with hip or knee osteoarthritis: translation into Dutch, cross-cultural adaptation and reliability assessment. PLoS ONE 10(12):e0146119
37.
go back to reference De Andrés J et al (2012) Cultural adaptation and validation of the painDETECT scale into Spanish. Clin J Pain 28(3):243–253PubMed De Andrés J et al (2012) Cultural adaptation and validation of the painDETECT scale into Spanish. Clin J Pain 28(3):243–253PubMed
38.
go back to reference Alkan H et al (2013) Turkish version of the painDETECT questionnaire in the assessment of neuropathic pain: a validity and reliability study. Pain Med 14(12):1933–1943PubMed Alkan H et al (2013) Turkish version of the painDETECT questionnaire in the assessment of neuropathic pain: a validity and reliability study. Pain Med 14(12):1933–1943PubMed
39.
go back to reference Matsubayashi Y et al (2013) Validity and reliability of the Japanese version of the painDETECT questionnaire: a multicenter observational study. PLoS ONE 8(9):68013 Matsubayashi Y et al (2013) Validity and reliability of the Japanese version of the painDETECT questionnaire: a multicenter observational study. PLoS ONE 8(9):68013
40.
go back to reference Gudala K, Ghai B, Bansal D (2017) Neuropathic pain assessment with the painDETECT questionnaire: cross-cultural adaptation and psychometric evaluation to Hindi. Pain Pract 17(8):1042–1049PubMed Gudala K, Ghai B, Bansal D (2017) Neuropathic pain assessment with the painDETECT questionnaire: cross-cultural adaptation and psychometric evaluation to Hindi. Pain Pract 17(8):1042–1049PubMed
41.
go back to reference Sung JK et al (2017) Korean version of the painDETECT questionnaire: a study for cultural adaptation and validation. Pain Pract 17(4):494–504PubMed Sung JK et al (2017) Korean version of the painDETECT questionnaire: a study for cultural adaptation and validation. Pain Pract 17(4):494–504PubMed
42.
go back to reference Cappelleri JC et al (2015) A cross-sectional study examining the psychometric properties of the painDETECT measure in neuropathic pain. J Pain Res 8:159–167PubMedPubMedCentral Cappelleri JC et al (2015) A cross-sectional study examining the psychometric properties of the painDETECT measure in neuropathic pain. J Pain Res 8:159–167PubMedPubMedCentral
43.
go back to reference Freynhagen R et al (2016) The painDETECT project: far more than a screening tool on neuropathic pain. Curr Med Res Opin 32(6):1033–1057PubMed Freynhagen R et al (2016) The painDETECT project: far more than a screening tool on neuropathic pain. Curr Med Res Opin 32(6):1033–1057PubMed
44.
go back to reference Freynhagen R et al (2006) PainDETECT: a new screening questionnaire to identify neuropathic components in patients with back pain. Curr Med Res Opin 22(10):1911–1920 Freynhagen R et al (2006) PainDETECT: a new screening questionnaire to identify neuropathic components in patients with back pain. Curr Med Res Opin 22(10):1911–1920
45.
go back to reference Bellamy N et al (2002) Clinimetric properties of the AUSCAN Osteoarthritis Hand Index: an evaluation of reliability, validity and responsiveness. Osteoarthritis Cartilage 10(11):863–869PubMed Bellamy N et al (2002) Clinimetric properties of the AUSCAN Osteoarthritis Hand Index: an evaluation of reliability, validity and responsiveness. Osteoarthritis Cartilage 10(11):863–869PubMed
46.
go back to reference Khan WS et al (2008) The ’M2 DASH’-Manchester-modified disabilities of arm shoulder and hand score. Hand (N Y) 3(3):240–244 Khan WS et al (2008) The ’M2 DASH’-Manchester-modified disabilities of arm shoulder and hand score. Hand (N Y) 3(3):240–244
47.
go back to reference Beaton DE et al (2001) Measuring the whole or the parts? Validity, reliability, and responsiveness of the disabilities of the arm, shoulder and hand outcome measure in different regions of the upper extremity. J Hand Ther 14(2):128–146PubMed Beaton DE et al (2001) Measuring the whole or the parts? Validity, reliability, and responsiveness of the disabilities of the arm, shoulder and hand outcome measure in different regions of the upper extremity. J Hand Ther 14(2):128–146PubMed
48.
go back to reference Solway SBD, McConnell S, Bombardier C (2002) The DASH outcome measure user’s manual Solway SBD, McConnell S, Bombardier C (2002) The DASH outcome measure user’s manual
49.
go back to reference Woolacott NF, Corbett MS, Rice SJ (2012) The use and reporting of WOMAC in the assessment of the benefit of physical therapies for the pain of osteoarthritis of the knee: findings from a systematic review of clinical trials. Rheumatology (Oxford) 51(8):1440–1446 Woolacott NF, Corbett MS, Rice SJ (2012) The use and reporting of WOMAC in the assessment of the benefit of physical therapies for the pain of osteoarthritis of the knee: findings from a systematic review of clinical trials. Rheumatology (Oxford) 51(8):1440–1446
50.
go back to reference Veehof MM et al (2002) Psychometric qualities of the Dutch language version of the disabilities of the arm, shoulder, and hand questionnaire (DASH-DLV). J Hand Ther 15(4):347–354PubMed Veehof MM et al (2002) Psychometric qualities of the Dutch language version of the disabilities of the arm, shoulder, and hand questionnaire (DASH-DLV). J Hand Ther 15(4):347–354PubMed
51.
go back to reference Bellamy N et al (1988) Validation study of WOMAC: a health status instrument for measuring clinically important patient relevant outcomes to antirheumatic drug therapy in patients with osteoarthritis of the hip or knee. J Rheumatol 15(12):1833–1840PubMed Bellamy N et al (1988) Validation study of WOMAC: a health status instrument for measuring clinically important patient relevant outcomes to antirheumatic drug therapy in patients with osteoarthritis of the hip or knee. J Rheumatol 15(12):1833–1840PubMed
52.
go back to reference Groningen R (2012) Het meten van de algemene gezondheidstoestand met de Rand-36:24–28 Groningen R (2012) Het meten van de algemene gezondheidstoestand met de Rand-36:24–28
53.
go back to reference Ware JE (1993) SF-36 Health Survey Manual and Interpretation Guide. The Health Institute, New England Medical Center - Boston Ware JE (1993) SF-36 Health Survey Manual and Interpretation Guide. The Health Institute, New England Medical Center - Boston
54.
go back to reference Jenkinson C, Coulter A, Wright L (1993) Short form 36 (SF36) health survey questionnaire: normative data for adults of working age. BMJ 306(6890):1437–1440PubMedPubMedCentral Jenkinson C, Coulter A, Wright L (1993) Short form 36 (SF36) health survey questionnaire: normative data for adults of working age. BMJ 306(6890):1437–1440PubMedPubMedCentral
56.
go back to reference Fu K, Robbins SR, McDougall JJ (2018) Osteoarthritis: the genesis of pain. Rheumatology (Oxford) 57(suppl_4):iv43–iv50 Fu K, Robbins SR, McDougall JJ (2018) Osteoarthritis: the genesis of pain. Rheumatology (Oxford) 57(suppl_4):iv43–iv50
57.
go back to reference Hunter DJ, Bierma-Zeinstra S (2019) Osteoarthritis. Lancet 393(10182):1745–1759PubMed Hunter DJ, Bierma-Zeinstra S (2019) Osteoarthritis. Lancet 393(10182):1745–1759PubMed
59.
go back to reference van Hecke O et al (2014) Neuropathic pain in the general population: a systematic review of epidemiological studies. Pain 155(4):654–662PubMed van Hecke O et al (2014) Neuropathic pain in the general population: a systematic review of epidemiological studies. Pain 155(4):654–662PubMed
60.
go back to reference French HP, Smart KM, Doyle F (2017) Prevalence of neuropathic pain in knee or hip osteoarthritis: a systematic review and meta-analysis. Semin Arthritis Rheum 47(1):1–8PubMed French HP, Smart KM, Doyle F (2017) Prevalence of neuropathic pain in knee or hip osteoarthritis: a systematic review and meta-analysis. Semin Arthritis Rheum 47(1):1–8PubMed
61.
go back to reference Baron R, Binder A, Wasner G (2010) Neuropathic pain: diagnosis, pathophysiological mechanisms, and treatment. Lancet Neurol 9(8):807–819PubMed Baron R, Binder A, Wasner G (2010) Neuropathic pain: diagnosis, pathophysiological mechanisms, and treatment. Lancet Neurol 9(8):807–819PubMed
Metadata
Title
Low prevalence of neuropathic-like pain symptoms in long-term controlled acromegaly
Authors
Victoria R. van Trigt
Iris C. M. Pelsma
Herman M. Kroon
Alberto M. Pereira
Coen van der Meulen
Margreet Kloppenburg
Nienke R. Biermasz
Kim M. J. A. Claessen
Publication date
01-04-2022
Publisher
Springer US
Published in
Pituitary / Issue 2/2022
Print ISSN: 1386-341X
Electronic ISSN: 1573-7403
DOI
https://doi.org/10.1007/s11102-021-01190-z

Other articles of this Issue 2/2022

Pituitary 2/2022 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.